Spots Global Cancer Trial Database for transformed follicular lymphoma
Every month we try and update this database with for transformed follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | NCT01397825 | Diffuse Large B... Transformed Fol... Mantle Cell Lym... Burkitt's Lymph... | Alisertib (MLN8... Rituximab Vincristine | 18 Years - | Takeda | |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | NCT01897571 | B-cell Lymphoma... Advanced Solid ... Diffuse Large B... Follicular Lymp... Transformed Fol... Primary Mediast... | Tazemetostat Prednisolone Tazemetostat | 16 Years - | Ipsen | |
| CT-011 MAb in DLBCL Patients Following ASCT | NCT00532259 | Lymphoma, Large... Lymphoma, Mixed... Primary Mediast... | CT-011 | 18 Years - | CureTech Ltd | |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | NCT01897571 | B-cell Lymphoma... Advanced Solid ... Diffuse Large B... Follicular Lymp... Transformed Fol... Primary Mediast... | Tazemetostat Prednisolone Tazemetostat | 16 Years - | Ipsen | |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | NCT01397825 | Diffuse Large B... Transformed Fol... Mantle Cell Lym... Burkitt's Lymph... | Alisertib (MLN8... Rituximab Vincristine | 18 Years - | Takeda | |
| Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | NCT04833504 | Diffuse Large B... Mantle Cell Lym... Transformed Fol... Primary Mediast... | CD19 CAR-T Expr... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma | NCT02082977 | Cancer Neoplasms | GSK2816126 | 18 Years - | GlaxoSmithKline | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
